ID | 119253 |
著者 |
北村, 直也
Kochi University
Sento, Shinya
Kochi University
Yoshizawa, Yasumasa
Kochi University
Sasabe, Eri
Kochi University
Yamamoto, Tetsuya
Kochi University
|
キーワード | head and neck squamous cell carcinoma
molecular targeted therapy
cetuximab
immune checkpoint inhibitor
multi-oncogene panel test
photoimmunotherapy
|
資料タイプ |
学術雑誌論文
|
抄録 | In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.
|
掲載誌名 |
International Journal of Molecular Sciences
|
ISSN | 14220067
|
出版者 | MDPI
|
巻 | 22
|
号 | 1
|
開始ページ | 240
|
発行日 | 2020-12-29
|
権利情報 | This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
歯学系
|